Clinical Trials Logo

Clinical Trial Summary

Tri-split face study of skin resurfacing modalities for the treatment of melasma, comparing the medium depth trichloroacetic acid peel, CO2 laser and Qs-NdYag laser.

Clinical Trial Description

Melasma is an acquired chronic and relapsing hyperpigmentation disorder, with a significant negative impact on the quality of life of patients. Melasma is more common in patients with skin of color and has also been linked to chronic ultraviolet (UV) and heat exposure, family history and hormonal factors. There are several studies in the literature using various therapies for melasma, including sun protection, topical therapies, lasers and chemical peels. However, many of these studies vary greatly in their efficacies and side effect profiles, due to varying and undelineated pre and post-op procedure regimens. Side effects of post-inflammatory hyper and hypopigmentation and rebound are reported in these studies. The investigators would like to conduct a tri-split face study that compares a 22% trichloroacetic acid (TCA) deep medium peel with an ablative fractionated CO2 laser and more pigment selective Q-switched (Qs) Nd:YAG laser. To minimize possible post-procedure side effects and melasma rebound, the investigators will perform above treatments in conjunction with an optimal skincare regimen, starting 6 weeks before and continuing after the treatments. The investigators will perform the 22% TCA chemical peel, CO2 laser and Qs-Nd:YAG at 6 weeks after the start of the skincare regimen, and repeat treatments with Qs-Nd:YAG at weeks 8, 10, and 12. The investigators will assess participants using standardized photos in conjunction with UV imaging (Visia CR) at weeks 0, 6, 16, 20 and 24 (6 months), by measuring the modified melasma area and severity index (mMASI) scores and visual analog scale (VAS) scores as graded by participants as well as by blinded physicians based on photos and UV imaging. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT02892071
Study type Interventional
Source University of Pittsburgh
Contact Suzan Obagi, MD
Phone 7249407546
Status Not yet recruiting
Phase Phase 1
Start date December 2018
Completion date September 2020

See also
  Status Clinical Trial Phase
Completed NCT01695356 - Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma Phase 4
Completed NCT02138539 - Evaluation of an Herbal-Based De-Pigmenting System Phase 4
Recruiting NCT01661556 - Clinical Trial of Hydroquinone Versus Miconazol in Melasma Phase 4
Completed NCT01001624 - Melanil in the Treatment of Melasma Phase 3
Recruiting NCT03686787 - Oral Tranexamic Acid and Laser for Treatment of Melasma Phase 4
Completed NCT00472966 - Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma Phase 4
Completed NCT00500162 - Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma Phase 4
Recruiting NCT03308370 - Platelet Rich Plasma in Treatment of Melasma Phase 3
Completed NCT01162850 - Oral Polypodium Leucotomos for Melasma N/A
Completed NCT00467233 - Study of Acid Peel and Laser for the Treatment of Melasma N/A
Completed NCT00469183 - Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma Phase 4
Completed NCT02730819 - Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma Phase 2
Completed NCT03674203 - Efficacy of Platelet-rich Plasma in for Melasma Treatment Phase 2
Completed NCT03040089 - Efficacy and Safety of Picosecond, Neodymium-doped Yttrium Aluminum Garnet Laser Therapy Using 1,064 nm and 595 nm N/A
Completed NCT02061839 - Prevention of Melasma Relapse During Summertime N/A
Completed NCT01092884 - Polypodium Leucotomos Extract for the Treatment of Melasma N/A
Completed NCT01245881 - Fractional Photothermolysis for Treating Melasma N/A
Completed NCT03751163 - Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma Phase 3
Not yet recruiting NCT03153852 - Modified Jessner's Solution With Trichloroacetic Acid Versus Glycolic Acid With Trichloroacetic Acid Phase 4
Completed NCT02095756 - Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma N/A